Sandra D Algaze

Title(s)Assistant Professor of Clinical Medicine
SchoolKeck School of Medicine of Usc
Address1520 San Pablo St.
Health Sciences Campus
Los Angeles CA 90033
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Sandra Algaze is an Assistant Professor of Medicine in the Division of Medical Oncology at the University of Southern California focusing on gastrointestinal cancers. Dr. Algaze completed her residency in Internal Medicine at the University of Miami, Jackson Memorial Hospital and her clinical fellowship in Hematology and Oncology at University of Southern California, Los Angeles County Hospital, where she served as a chief fellow.

    Her research endeavors focus on the discovery of innovative pathways in cancer pathogenesis, metastases and treatment resistance, the development of novel therapies for gastrointestinal tumors, and the assessment of predictive and prognostic biomarkers and molecular profiles. Additionally, she is actively investigating and working to address the complexities surrounding the care of older patients with cancer, and healthcare disparities arising from barriers to specialty care access and the underrepresentation of minorities in cancer clinical trials. Notably, she was part of the inaugural cohort of the Robert A. Winn Diversity in Clinical Trials: Career Development Award (Winn CDA).

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. Oncologist. 2024 Jul 10. Morgenstern-Kaplan D, Kareff SA, Trabolsi A, Rodriguez E, Krause H, Ribeiro JR, Tan H, Antonarakis ES, Lou E, Nagasaka M, Algaze S, Lenz HJ, Liu SV, Halmos B, Hoon DSB, Seeber A, Ma PC, El-Deiry WS, Vanderwalde AM, Lopes G. PMID: 38986529.
      View in: PubMed   Mentions:    Fields:    
    2. Rectal Cancer Survival for Residual Carcinoma In Situ Vs. Pathologic Complete Response After Neoadjuvant Therapy. Dis Colon Rectum. 2024 Mar 18. Kohrman NM, Wlodarczyk JR, Ding L, McAndrew NP, Algaze SD, Cologne KG, Lee SW, Koller SE. PMID: 38498775.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer. Eur J Cancer. 2024 Apr; 201:113914. Arai H, Yang Y, Baca Y, Millstein J, Denda T, Ou FS, Innocenti F, Takeda H, Kubota Y, Doi A, Horie Y, Umemoto K, Izawa N, Wang J, Battaglin F, Jayachandran P, Algaze S, Soni S, Zhang W, Goldberg RM, Hall MJ, Scott AJ, Hwang JJ, Lou E, Weinberg BA, Marshall J, Goel S, Xiu J, Michael Korn W, Venook AP, Sunakawa Y, Lenz HJ. PMID: 38359495.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value. J Immunother Cancer. 2024 01 11; 12(1). Battaglin F, Baca Y, Millstein J, Yang Y, Xiu J, Arai H, Wang J, Ou FS, Innocenti F, Mumenthaler SM, Jayachandran P, Kawanishi N, Lenz A, Soni S, Algaze S, Zhang W, Khoukaz T, Roussos Torres E, Seeber A, Abraham JP, Lou E, Philip PA, Weinberg BA, Shields AF, Goldberg RM, Marshall JL, Venook AP, Korn WM, Lenz HJ. PMID: 38212126; PMCID: PMC10806545.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions. Oncogene. 2023 02; 42(9):627-637. Jayachandran P, Battaglin F, Strelez C, Lenz A, Algaze S, Soni S, Lo JH, Yang Y, Millstein J, Zhang W, Shih JC, Lu J, Mumenthaler SM, Spicer D, Neman J, Roussos Torres ET, Lenz HJ. PMID: 36650218; PMCID: PMC9957733.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    6. Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatment. Oncogene. 2022 10; 41(43):4769-4778. Battaglin F, Jayachandran P, Strelez C, Lenz A, Algaze S, Soni S, Lo JH, Yang Y, Millstein J, Zhang W, Roussos Torres ET, Shih JC, Mumenthaler SM, Neman J, Lenz HJ. PMID: 36182970; PMCID: PMC10591256.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    7. Hepatitis B Reactivation: A Potentially Serious Complication of Chemotherapy for Solid Tumors. Advance in Cancer Research & Clinical Imaging. 2020; 2(3). Algaze S, Donovan J, Kang I. View Publication.
    8. Moving Beyond Chemotherapy for Pancreaticobiliary Tumors: Targeted and Immunotherapy Strategies. American Society of Clinical Oncology Educational Book. 2020; e333-e343. Allen R, Halpern N, Algaze S, Golan T, El-Khoueiry AB, Shroff RT.
    9. A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia. Acta Haematol. 2020; 143(3):244-249. Piatek CI, Bocian H, Algaze S, Weitz IC, O'Connell C, Liebman HA. PMID: 31665725.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    10. Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin. BMJ Case Rep. 2018 Mar 09; 2018. Algaze SD, Park W, Harrington TJ, Mudad R. PMID: 29523604; PMCID: PMC5847928.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    11. The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease. Biomedicines. 2017 Nov 29; 5(4). Ali R, Ramdial J, Algaze S, Beitinjaneh A. PMID: 29186076; PMCID: PMC5744091.
      View in: PubMed   Mentions: 9